NexImmune (NEXI) Short Interest Ratio & Short Volume $0.24 +0.00 (+1.21%) (As of 02:14 PM ET) Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NexImmune Short Interest DataNexImmune (NEXI) has a short interest of 16,000 shares, representing 1.39% of the float (the number of shares available for trading by the public). This marks a -3.61% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 804,114 shares to cover all short positions.Current Short Interest16,000 sharesPrevious Short Interest16,600 sharesChange Vs. Previous Month-3.61%Dollar Volume Sold Short$44,158.40Short Interest Ratio0.9 Days to CoverLast Record DateJune 30, 2024Outstanding Shares1,390,000 sharesFloat Size1,150,000 sharesShort Percent of Float1.39%Today's Trading Volume2,796 sharesAverage Trading Volume804,114 sharesToday's Volume Vs. Average0% Short Selling NexImmune? Sign up to receive the latest short interest report for NexImmune and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNEXI Short Interest Over TimeNEXI Days to Cover Over TimeNEXI Percentage of Float Shorted Over Time Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW NexImmune Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/202416,000 shares $44,158.40 -3.6%1.4%0.9 $2.76 6/15/202416,600 shares $48,970.00 +35.0%1.4%0.9 $2.95 5/31/202412,300 shares $37,638.00 +5.1%1.1%0.5 $3.06 5/15/202411,700 shares $40,540.50 +88.7%1.0%0.2 $3.47 4/30/20246,200 shares $20,832.00 -23.5%0.6%0.1 $3.36 4/15/20248,100 shares $28,755.00 -54.5%0.9%0 $3.55 Get the Latest News and Ratings for NEXI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter. 3/31/202417,800 shares $99,858.00 -49.4%2.3%0 $5.61 3/15/202435,200 shares $203,808.00 +122.8%4.5%0 $5.79 2/29/202415,800 shares $105,860.00 -63.4%2.2%0 $6.70 2/15/202443,200 shares $364,608.00 -69.5%5.9%0 $8.44 1/31/2024141,400 shares $2.12 million -2.8%21.5%0.1 $15.00 1/15/2024145,400 shares $1.45 million +513.5%22.1%0.1 $9.96 12/31/202323,700 shares $52,614.00 -33.6%3.6%0 $2.22 12/15/202335,700 shares $87,822.00 +526.3%5.4%0.1 $2.46 11/30/20235,700 shares $14,136.00 -12.3%0.9%0 $2.48 11/15/20236,500 shares $15,860.00 -25.3%1.0%0.4 $2.44 10/31/20238,700 shares $32,364.00 +45.0%1.4%0.7 $3.72 10/15/20236,000 shares $28,545.00 -95.6%0.9%1.1 $4.76 9/30/2023134,900 shares $28,315.51 +21.3%0.9%1.6 $0.21 9/15/2023111,200 shares $28,912.00 +34.5%0.7%1.2 $0.26 8/31/202382,700 shares $17,706.07 -59.0%0.5%0.6 $0.21 8/15/2023201,600 shares $49,593.60 +5.7%1.3%1.2 $0.25 7/31/2023190,800 shares $55,389.24 -33.5%1.2%0.7 $0.29 7/15/2023286,700 shares $77,695.70 -19.3%1.8%1 $0.27 6/30/2023355,400 shares $100,151.72 +47.7%2.3%1.3 $0.28 6/15/2023240,600 shares $78,483.72 -24.2%1.5%0.8 $0.33 5/31/2023317,200 shares $101,662.60 +49.2%2.0%1.3 $0.32 5/15/2023212,600 shares $59,549.26 -0.6%1.3%0.8 $0.28 4/30/2023213,900 shares $77,239.29 -32.0%1.4%0.2 $0.36 4/15/2023314,700 shares $121,190.97 -7.3%2.0%0.3 $0.39 3/31/2023339,500 shares $129,010.00 -1.3%2.1%0.3 $0.38 3/15/2023344,000 shares $142,106.40 -18.1%2.0%0.3 $0.41 2/28/2023419,800 shares $180,514.00 +67.2%2.3%0.3 $0.43 2/15/2023251,100 shares $102,951.00 -3.1%1.4%0.2 $0.41 1/31/2023259,100 shares $105,350.06 +12.7%1.4%1 $0.41 1/15/2023229,900 shares $91,960.00 -42.1%1.2%0.9 $0.40 12/30/2022397,300 shares $96,583.63 +2.8%2.1%1.7 $0.24 12/15/2022386,600 shares $115,284.12 -3.8%2.1%2 $0.30 11/30/2022401,900 shares $178,041.70 -38.4%2.2%1.4 $0.44 11/15/2022652,500 shares $296,822.25 -13.9%3.5%0.9 $0.45When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! 10/31/2022758,100 shares $530,745.81 -13.9%4.4%1.1 $0.70 10/15/2022880,900 shares $615,749.10 -8.6%5.1%1.2 $0.70 9/30/2022963,700 shares $534,468.02 +29.4%5.5%0.6 $0.55 9/15/2022745,000 shares $584,750.50 +38.4%4.8%0.4 $0.78 8/31/2022538,500 shares $635,430.00 +13.2%3.6%0.3 $1.18 8/15/2022475,800 shares $599,508.00 +8.2%3.4%0.4 $1.26 7/31/2022439,800 shares $505,770.00 -3.5%3.1%0.4 $1.15 7/15/2022455,600 shares $833,748.00 -12.0%3.2%0.4 $1.83 6/30/2022517,700 shares $833,497.00 -48.2%3.6%2.9 $1.61 6/15/20221,000,000 shares $2.05 million -3.9%7.0%4.1 $2.05 5/31/20221,040,000 shares $2.37 million +9.1%7.2%4.2 $2.28 5/15/2022953,100 shares $1.92 million +7.6%6.6%4.2 $2.01 4/30/2022885,900 shares $1.87 million +8.8%6.1%3.9 $2.11 4/15/2022814,500 shares $2.42 million -5.8%5.6%3.8 $2.97 3/31/2022865,000 shares $3.64 million +46.6%6.0%4.5 $4.21 3/15/2022590,000 shares $1.13 million +7.8%4.0%5.1 $1.92 2/28/2022547,200 shares $1.36 million +5.1%3.7%5.8 $2.48 2/15/2022520,700 shares $1.30 million +9.0%3.2%6.8 $2.50 1/31/2022477,700 shares $1.51 million +13.2%2.9%7.6 $3.17 1/15/2022422,100 shares $1.57 million +5.5%2.6%8.2 $3.71 12/31/2021400,300 shares $1.85 million -5.2%2.4%8.2 $4.61 12/15/2021422,300 shares $2.21 million -2.2%2.6%8.5 $5.24 11/30/2021431,800 shares $3.41 million -6.2%2.6%5.9 $7.90 11/15/2021460,300 shares $4.66 million -4.7%2.8%5.5 $10.13 10/29/2021483,100 shares $5.50 million -5.4%2.9%5.4 $11.38 10/15/2021510,900 shares $6.55 million -14.2%3.1%5.9 $12.82 9/30/2021595,700 shares $9.02 million +94.1%3.6%7 $15.14 9/15/2021306,900 shares $4.89 million +4.3%1.9%3.8 $15.93 8/31/2021294,200 shares $4.14 million -1.9%1.8%5.6 $14.08 8/13/2021299,800 shares $4.25 million No Change1.8%8.2 $14.19 NEXI Short Interest - Frequently Asked Questions What is NexImmune's current short interest? Short interest is the volume of NexImmune shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 16,000 shares of NEXI short. 1.39% of NexImmune's shares are currently sold short. Learn More on NexImmune's current short interest. What is a good short interest ratio for NexImmune? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NEXI shares currently have a short interest ratio of 1.0. Learn More on NexImmune's short interest ratio. What is a good short interest percentage for NexImmune? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.39% of NexImmune's floating shares are currently sold short. Is NexImmune's short interest increasing or decreasing? NexImmune saw a decrease in short interest in June. As of June 30th, there was short interest totaling 16,000 shares, a decrease of 3.6% from the previous total of 16,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NexImmune's float size? NexImmune currently has issued a total of 1,390,000 shares. Some of NexImmune's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NexImmune currently has a public float of 1,150,000 shares. How does NexImmune's short interest compare to its competitors? 1.39% of NexImmune's shares are currently sold short. Here is how the short interest of companies compare to NexImmune: TFF Pharmaceuticals, Inc. (5.55%), ASLAN Pharmaceuticals Limited (1.40%), ZyVersa Therapeutics, Inc. (4.25%), Qualigen Therapeutics, Inc. (3.14%), Cyclacel Pharmaceuticals, Inc. (3.26%), Biodexa Pharmaceuticals Plc (11.50%), Elevai Labs, Inc. (56.82%), TC Biopharm (Holdings) Plc (12.25%), TRACON Pharmaceuticals, Inc. (6.64%), Seelos Therapeutics, Inc. (4.73%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.71 billion), TC Energy Co. ($2.95 billion), Moderna, Inc. ($2.63 billion), Royal Caribbean Cruises Ltd. ($2.53 billion), Paychex, Inc. ($2.03 billion), Cencora, Inc. ($2.03 billion), Tractor Supply ($1.91 billion), Rivian Automotive, Inc. ($1.78 billion), Chesapeake Energy Co. ($1.50 billion), and United Therapeutics Co. ($1.40 billion). View all of the most shorted stocks. What does it mean to sell short NexImmune stock? Short selling NEXI is an investing strategy that aims to generate trading profit from NexImmune as its price is falling. NEXI shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NexImmune? A short squeeze for NexImmune occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NEXI, which in turn drives the price of the stock up even further. How often is NexImmune's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NEXI, twice per month. The most recent reporting period available is June, 30 2024. More Short Interest Resources from MarketBeat Related Companies TFF Pharmaceuticals Short Interest Data ASLAN Pharmaceuticals Short Interest Data ZyVersa Therapeutics Short Interest Data Qualigen Therapeutics Short Interest Data Cyclacel Pharmaceuticals Short Interest Data Biodexa Pharmaceuticals Short Interest Data Elevai Labs Short Interest Data TC Biopharm Short Interest Data Smart for Life Short Interest Data Seelos Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NEXI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
